Subcutaneous vedolizumab drug de-escalation in inflammatory bowel disease: protocol for a multicentre randomised controlled study

STRENGTHS AND LIMITATIONS OF THIS STUDY

  • The multicentre randomised controlled design minimises systematic bias.

  • This study includes a prospective, trial-based economic evaluation.

  • The adaptive treatment strategy evaluated is clinically attractive.

  • Endoscopy is not mandatory in the study, although it remains the gold standard for confirmation of a disease relapse.

  • Blinding is not possible due to the absence of a sham intervention.

  • Introduction

    Crohn’s disease (CD) and ulcerative colitis (UC) are the two main entities of inflammatory bowel disease (IBD). IBD is a chronic inflammatory disorder of the gastrointestinal tract that is characterised by relapsing and remitting episodes. Vedolizumab (VDZ) is an approved and extensively used effective maintenance treatment for IBD, with a gut-selective mode of action.1 2 It is a humanised IgG1 monoclonal antibody that binds specifically to α4β7 integrins on a variety of inflammatory cells….
    This post was originally published on https://bmjopen.bmj.com